- Home
- ECBK vs NBTX Comparison
ECBK vs NBTX Comparison
Compare ECBK & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- NBTX
- Stock Information
- Founded
- ECBK 1919
- NBTX 2003
- Country
- ECBK United States
- NBTX France
- Employees
- ECBK N/A
- NBTX N/A
- Industry
- ECBK Banks
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- NBTX Health Care
- Exchange
- ECBK Nasdaq
- NBTX Nasdaq
- Market Cap
- ECBK 151.0M
- NBTX 167.8M
- IPO Year
- ECBK N/A
- NBTX 2020
- Fundamental
- Price
- ECBK $16.22
- NBTX $4.10
- Analyst Decision
- ECBK
- NBTX Strong Buy
- Analyst Count
- ECBK 0
- NBTX 1
- Target Price
- ECBK N/A
- NBTX $8.00
- AVG Volume (30 Days)
- ECBK 15.7K
- NBTX 11.5K
- Earning Date
- ECBK 04-24-2025
- NBTX 04-02-2025
- Dividend Yield
- ECBK N/A
- NBTX N/A
- EPS Growth
- ECBK 17.87
- NBTX N/A
- EPS
- ECBK 0.57
- NBTX N/A
- Revenue
- ECBK $26,906,000.00
- NBTX N/A
- Revenue This Year
- ECBK N/A
- NBTX N/A
- Revenue Next Year
- ECBK N/A
- NBTX $221.06
- P/E Ratio
- ECBK $28.67
- NBTX N/A
- Revenue Growth
- ECBK 5.99
- NBTX N/A
- 52 Week Low
- ECBK $11.95
- NBTX $2.76
- 52 Week High
- ECBK $16.99
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- ECBK 52.29
- NBTX 64.63
- Support Level
- ECBK $15.97
- NBTX $3.64
- Resistance Level
- ECBK $16.55
- NBTX $4.20
- Average True Range (ATR)
- ECBK 0.38
- NBTX 0.15
- MACD
- ECBK -0.04
- NBTX 0.04
- Stochastic Oscillator
- ECBK 45.78
- NBTX 88.51
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.